LOADING
Comparing Merck & Company (MRK) and Thermo Fisher Scientific (TMO), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | MRK | TMO |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $283.1B | $173.4B |
| P/E Ratio | 15.7 | 25.6 |
| Forward P/E | 22.4 | 18.8 |
| PEG Ratio | 3.50 | 1.73 |
| EPS | $7.28 | $18.20 |
| Revenue Growth (YoY) | 5.0% | 7.2% |
| Profit Margin | 28.1% | 15.0% |
| Return on Equity | 36.9% | 13.0% |
| Dividend Yield | 2.87% | -- |
| Beta | 0.28 | 0.97 |
| 52-Week High | $124.22 | $643.35 |
| 52-Week Low | $70.74 | $384.44 |
| Volume | -- | -- |
Merck & Company is the larger company by market capitalization. Merck & Company trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.